Revance Therapeutics Inc. (Nasdaq: RVNC) reported positive results from two Phase 3 clinic trials of RT002 to treat frown lines sending the stock price soaring $8.75 to close at $34.75.
Revance Therapeutics reports positive trial results
December 05, 2017 at 16:21 PM EST
